Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · April 26, 2022

Efficacy and Safety of Cotadutide in Patients With Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Efficacy and safety of cotadutide, a dual GLP-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Diabetes Obes Metab 2022 Apr 11;[EPub Ahead of Print], VER Parker, T Hoang, H Schlichthaar, FW Gibb, B Wenzel, MG Posch, L Rose, YT Chang, M Petrone, L Hansen, P Ambery, L Jermutus, HJL Heerspink, RJ McCrimmon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading